December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.94 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
88 89 Next >
News headline image
Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too) ↗
Here are seven Warren Buffett stocks to sell that the Oracle himself has decided that they've lost their luster. 
Via InvestorPlace
News headline image
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
News headline image
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 ↗
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder 
Via InvestorPlace
News headline image
Smart Money Is Betting Big In BMY Options ↗
 
Via Benzinga
News headline image
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity? ↗
BMY is offering a 6% yield and trading for less than 9 times earnings. 
Via Talk Markets
News headline image
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug ↗
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market... 
Via Benzinga
News headline image
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
News headline image
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients ↗
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC. 
Via Benzinga
News headline image
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday ↗
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates. 
Via Benzinga
News headline image
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
2 No-Brainer Dividend Stocks You Can Buy With $100 in June ↗
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come. 
Via The Motley Fool
News headline image
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies ↗
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
7 Underappreciated Stocks With 25% Return Potential in 2024 ↗
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention. 
Via InvestorPlace
News headline image
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare ↗
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
News headline image
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
3 Blue-Chip Stocks to Buy at 52-Week Lows in May ↗
These three blue-chip stocks at a 52-week low could provide investors with a good opportunity to open a new position or double an old one. 
Via InvestorPlace
News headline image
S&P 500 Earnings Dashboard 24Q1 - Saturday, May 25 ↗
Of the 480 companies in the S&P 500 that have reported earnings to date for 24Q1, 77.9% reported above analyst expectations. This compares to a long-term average of 66%. 
Via Talk Markets
Topics Stocks
News headline image
Retail Earnings & Consumer Spending: A Closer Look ↗
The U.S. economy is chugging along, with growth moderately decelerating under the Fed’s tight monetary policy. Most of the Q1 earnings season is behind us, with results from 481 S&P 500 companies... 
Via Talk Markets
Topics Economy Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.